| Distribution | Full List | Categories |
| by Country | by Vaccine |
| PEOPLE VACCINATED | LAST 7 DAYS | |||||
| countries over 1M population |
1st dose |
last dose |
1st dose |
last dose |
any dose |
|
| United Arab Emirates |
96.5% 9,544,097 |
86.5% 8,555,071 |
0.8% | 1.0% |
2.1% 204k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinopharm/Wuhan, Sputnik V | ||||||
| Portugal |
88.0% 8,975,593 |
86.1% 8,782,671 |
0.2% | 0.5% |
0.6% 57k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Cuba |
85.8% 9,719,850 |
60.0% 6,790,452 |
0.8% | 4.9% |
14.7% 1,665k |
|
| Abdala, Soberana02 | ||||||
| Chile |
84.3% 16,125,103 |
75.2% 14,372,184 |
1.1% | 0.8% |
4.2% 800k |
|
| CanSino, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac | ||||||
| Qatar |
81.9% 2,360,308 |
77.0% 2,218,292 |
0.9% 24k |
|||
| Moderna, Pfizer/BioNTech | ||||||
| Cambodia |
81.3% 13,593,910 |
75.5% 12,617,254 |
0.6% | 6.7% |
10.3% 1,729k |
|
| Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac | ||||||
| Spain |
81.1% 37,899,559 |
79.3% 37,086,628 |
0.2% | 0.3% |
0.5% 218k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Singapore |
81.0% 4,741,030 |
80.1% 4,685,253 |
0.3% | 1.3% |
3.1% 184k |
|
| Moderna, Pfizer/BioNTech, Sinovac | ||||||
| Uruguay |
79.3% 2,753,911 |
75.1% 2,608,885 |
0.2% | 0.2% |
2.6% 91k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac | ||||||
| South Korea |
79.0% 40,513,091 |
66.8% 34,265,084 |
0.7% | 5.9% |
6.7% 3,416k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Canada |
78.5% 29,623,275 |
73.7% 27,809,792 |
0.5% | 0.8% |
1.6% 589k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Malaysia |
78.0% 25,256,675 |
71.2% 23,052,952 |
0.7% | 3.0% |
3.7% 1,197k |
|
| CanSino, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac | ||||||
| France |
78.0% 50,892,531 |
69.7% 45,467,286 |
0.3% | 0.5% |
1.4% 926k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Norway |
77.3% 4,192,508 |
68.4% 3,709,145 |
0.1% | 0.3% |
0.4% 21k |
|
| Moderna, Pfizer/BioNTech | ||||||
| Denmark |
77.1% 4,467,373 |
75.9% 4,397,832 |
0.1% | 0.2% |
0.2% 14k |
|
| Johnson&Johnson, Moderna, Pfizer/BioNTech | ||||||
| Ireland |
76.8% 3,792,047 |
75.5% 3,729,385 |
0.1% | 0.3% |
0.4% 20k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Italy |
76.6% 46,320,599 |
70.2% 42,423,310 |
0.7% | 0.9% |
2.1% 1,252k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| China |
76.5% 1,100,842,000 |
72.8% 1,047,872,000 |
||||
| CanSino, Sinopharm/Beijing, Sinopharm/Wuhan, Sinovac, ZF2001 | ||||||
| Japan |
75.9% 95,991,219 |
68.1% 86,088,680 |
1.5% | 2.6% |
4.1% 5,199k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Finland |
75.6% 4,187,851 |
67.2% 3,724,752 |
0.4% | 1.8% |
2.2% 124k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Belgium |
74.7% 8,657,592 |
73.4% 8,507,346 |
0.2% | 0.2% |
0.4% 46k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| New Zealand |
74.5% 3,593,488 |
58.8% 2,837,706 |
2.3% | 7.1% |
9.4% 454k |
|
| Pfizer/BioNTech | ||||||
| Brazil |
73.6% 156,532,157 |
50.4% 107,093,421 |
0.8% | 2.8% |
3.5% 7,376k |
|
| Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac | ||||||
| United Kingdom |
72.9% 49,462,425 |
66.9% 45,400,990 |
0.4% | 0.3% |
0.6% 435k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Australia |
72.4% 18,459,101 |
57.9% 14,753,069 |
2.2% | 5.1% |
7.3% 1,854k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Israel |
71.8% 6,210,282 |
65.9% 5,705,084 |
0.2% | 0.1% |
1.2% 103k |
|
| Moderna, Pfizer/BioNTech | ||||||
| Sweden |
71.5% 7,223,301 |
67.5% 6,819,230 |
0.2% | 0.7% |
2.0% 200k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Costa Rica |
70.6% 3,597,302 |
49.6% 2,527,143 |
1.4% | 2.6% |
4.0% 203k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Argentina |
69.8% 31,547,968 |
54.8% 24,758,547 |
2.5% | 1.6% |
4.1% 1,839k |
|
| CanSino, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
| Netherlands |
69.6% 11,920,567 |
46.5% 7,959,975 |
0.5% 91k |
|||
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Mauritius |
69.3% 881,907 |
65.4% 831,887 |
0.9% | 1.3% |
2.2% 28k |
|
| Covaxin, Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Sri Lanka |
69.1% 14,785,189 |
59.9% 12,818,379 |
0.3% | 1.6% |
1.9% 406k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
| Bahrain |
68.9% 1,171,634 |
66.7% 1,134,813 |
0.1% | 0.2% |
2.4% 40k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
| Saudi Arabia |
68.8% 23,967,472 |
60.0% 20,895,225 |
0.6% | 1.8% |
2.3% 811k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Mongolia |
68.8% 2,254,074 |
65.2% 2,136,699 |
0.0% | 0.1% |
0.1% 3k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
| Panama |
68.6% 2,961,391 |
54.2% 2,340,962 |
0.2% | 0.5% |
1.5% 65k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Germany |
68.4% 57,326,792 |
65.4% 54,808,484 |
0.3% | 0.5% |
1.0% 878k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Ecuador |
66.4% 11,708,111 |
56.9% 10,032,731 |
0.8% | 0.3% |
1.1% 191k |
|
| CanSino, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac | ||||||
| United States |
66.2% 219,161,368 |
57.2% 189,487,793 |
0.5% | 0.5% |
1.8% 5,862k |
|
| Johnson&Johnson, Moderna, Pfizer/BioNTech | ||||||
| Lithuania |
65.6% 1,784,426 |
60.5% 1,645,708 |
0.5% | 0.2% |
1.3% 35k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| El Salvador |
65.5% 4,246,672 |
55.8% 3,616,154 |
0.7% | 0.7% |
2.8% 184k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac | ||||||
| Switzerland |
65.3% 5,653,845 |
61.7% 5,338,562 |
0.5% | 1.5% |
1.9% 167k |
|
| Moderna, Pfizer/BioNTech | ||||||
| Turkey |
65.2% 54,966,932 |
56.4% 47,585,869 |
0.4% | 1.1% |
1.8% 1,485k |
|
| Pfizer/BioNTech, Sinovac | ||||||
| Austria |
64.7% 5,822,953 |
61.6% 5,545,578 |
0.3% | 0.5% |
1.4% 129k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Taiwan |
63.2% 15,063,365 |
23.0% 5,478,056 |
5.3% | 3.3% |
8.6% 2,044k |
|
| Medigen, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Morocco |
63.0% 23,236,666 |
56.7% 20,925,569 |
0.5% | 2.0% |
4.1% 1,527k |
|
| Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
| Greece |
62.9% 6,558,235 |
60.6% 6,315,479 |
0.4% | 0.5% |
1.1% 118k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Hungary |
61.3% 5,926,446 |
59.0% 5,703,088 |
0.2% | 0.2% |
1.3% 123k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
| Hong Kong |
61.0% 4,570,019 |
58.1% 4,353,247 |
0.3% | 0.7% |
1.1% 79k |
|
| Pfizer/BioNTech, Sinovac | ||||||
| Dominican Republic |
58.7% 6,372,529 |
47.2% 5,121,120 |
2.0% | 1.2% |
4.0% 436k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac | ||||||
| Estonia |
58.3% 773,457 |
55.1% 730,372 |
0.5% | 0.6% |
0.9% 12k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Iran |
58.3% 48,956,693 |
30.0% 25,156,987 |
4.0% | 6.1% |
10.1% 8,498k |
|
| COVIran Barekat, Covaxin, Oxford/AstraZeneca, Sinopharm/Beijing, Soberana02, Sputnik V | ||||||
| Oman |
58.0% 2,959,586 |
44.9% 2,294,880 |
0.7% | 2.6% |
3.2% 166k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V | ||||||
| Czechia |
57.3% 6,136,389 |
56.3% 6,033,906 |
0.2% | 0.2% |
0.3% 38k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Colombia |
56.4% 28,697,781 |
38.8% 19,724,680 |
1.6% | 2.2% |
3.2% 1,653k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac | ||||||
| Latvia |
55.4% 1,044,754 |
50.2% 946,223 |
3.5% | 2.0% |
4.2% 79k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Slovenia |
54.9% 1,140,408 |
51.4% 1,068,240 |
0.2% | 1.0% |
1.2% 25k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Peru |
54.3% 17,911,223 |
42.9% 14,146,050 |
1.9% | 2.0% |
3.8% 1,268k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing | ||||||
| Mexico |
53.6% 69,105,502 |
39.8% 51,291,609 |
1.9% | 2.2% |
3.7% 4,817k |
|
| CanSino, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V | ||||||
| Poland |
53.0% 20,050,972 |
52.2% 19,756,793 |
0.2% | 0.3% |
0.9% 330k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Thailand |
52.9% 36,955,020 |
36.2% 25,287,543 |
3.3% | 3.3% |
6.9% 4,830k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac | ||||||
| India |
50.7% 700,140,298 |
20.8% 286,972,753 |
0.8% | 1.0% |
1.9% 25,773k |
|
| Covaxin, Oxford/AstraZeneca, Sputnik V | ||||||
| Azerbaijan |
49.1% 4,976,945 |
41.9% 4,249,138 |
0.7% | 1.1% |
1.9% 189k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V | ||||||
| Vietnam |
47.8% 46,493,751 |
19.0% 18,498,737 |
7.6% | 2.4% |
10.0% 9,763k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
| Tunisia |
45.8% 5,411,984 |
35.6% 4,205,797 |
1.1% | 1.1% |
2.0% 231k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V | ||||||
| Croatia |
45.6% 1,872,076 |
42.8% 1,757,089 |
0.4% | 0.5% |
0.8% 33k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Slovakia |
45.5% 2,484,409 |
41.8% 2,283,865 |
0.2% | 0.2% |
0.3% 16k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sputnik V | ||||||
| Serbia |
45.0% 3,064,730 |
43.1% 2,933,395 |
0.2% | 0.2% |
1.1% 73k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
| Trinidad and Tobago |
43.8% 612,861 |
40.8% 571,031 |
0.9% | 1.3% |
2.2% 30k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing | ||||||
| Kosovo |
43.0% 831,143 |
34.5% 666,265 |
0.4% | 3.0% |
3.4% 65k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Kazakhstan |
42.9% 8,054,450 |
38.2% 7,167,091 |
0.9% | 1.2% |
2.1% 394k |
|
| QazVac, Sinopharm/Beijing, Sputnik V | ||||||
| Paraguay |
40.2% 2,868,610 |
28.9% 2,058,067 |
0.4% | 0.8% |
1.3% 90k |
|
| Covaxin, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V | ||||||
| Indonesia |
39.8% 109,005,627 |
23.4% 64,008,898 |
2.8% | 2.0% |
4.8% 13,246k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac | ||||||
| Uzbekistan |
38.4% 12,861,301 |
17.3% 5,789,691 |
1.5% | 1.5% |
3.7% 1,230k |
|
| Moderna, Oxford/AstraZeneca, Sputnik V, ZF2001 | ||||||
| North Macedonia |
38.3% 799,027 |
36.4% 758,001 |
0.2% | 0.6% |
0.8% 17k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V | ||||||
| Timor |
37.6% 495,822 |
23.9% 315,033 |
2.1% | 1.6% |
3.7% 49k |
|
| Oxford/AstraZeneca, Sinovac | ||||||
| Jordan |
37.5% 3,830,249 |
33.5% 3,420,478 |
0.3% | 0.3% |
0.6% 65k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
| Bolivia |
37.3% 4,357,421 |
29.7% 3,465,762 |
0.6% | 1.1% |
1.5% 178k |
|
| Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
| Honduras |
35.5% 3,520,903 |
25.6% 2,537,900 |
1.9% | 0.6% |
2.4% 241k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sputnik V | ||||||
| Laos |
35.2% 2,560,372 |
25.3% 1,842,398 |
1.6% | 0.7% |
2.3% 164k |
|
| Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V | ||||||
| Venezuela |
34.9% 9,926,613 |
21.8% 6,190,629 |
0.4% | 0.5% |
0.9% 262k |
|
| Abdala, Sinopharm/Beijing, Sinopharm/Wuhan, Sputnik V | ||||||
| Russia |
34.4% 50,182,928 |
31.3% 45,702,564 |
0.6% | 0.6% |
1.2% 1,770k |
|
| EpiVacCorona, Sputnik V | ||||||
| Albania |
34.1% 982,467 |
29.9% 860,194 |
0.7% | 0.9% |
1.4% 39k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V | ||||||
| Romania |
34.1% 6,559,551 |
29.6% 5,689,257 |
2.0% | 0.7% |
2.2% 415k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Kuwait |
34.0% 1,452,148 |
21.6% 923,307 |
2.2% | 3.0% |
1.9% 81k |
|
| Pfizer/BioNTech | ||||||
| Pakistan |
29.4% 64,947,702 |
15.8% 34,809,848 |
1.3% | 1.4% |
2.6% 5,810k |
|
| CanSino, Covaxin, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V | ||||||
| Nepal |
28.9% 8,415,067 |
22.2% 6,470,195 |
0.3% | 0.0% |
0.4% 105k |
|
| Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Guatemala |
28.4% 5,086,999 |
16.9% 3,026,338 |
1.1% | 1.0% |
2.2% 385k |
|
| Moderna, Oxford/AstraZeneca | ||||||
| Palestine |
27.8% 1,416,215 |
23.0% 1,176,037 |
18.5% |
2.1% 107k |
||
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik Light, Sputnik V | ||||||
| WORLD |
27.5% 2,147,483,647 |
27.5% 2,147,483,647 |
||||
| Tajikistan |
26.4% 2,513,950 |
21.1% 2,011,987 |
0.5% | 1.2% |
1.7% 163k |
|
| Moderna, Oxford/AstraZeneca, Sinovac | ||||||
| Belarus |
26.1% 2,468,546 |
18.5% 1,749,584 |
2.5% | 1.3% |
3.8% 356k |
|
| Sinopharm/Beijing, Sputnik V | ||||||
| Georgia |
25.4% 1,013,828 |
22.7% 907,106 |
0.2% | 0.6% |
0.9% 34k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac | ||||||
| Philippines |
25.4% 27,836,530 |
22.5% 24,694,717 |
1.1% |
2.6% 2,839k |
||
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V | ||||||
| Lebanon |
25.0% 1,710,026 |
21.0% 1,434,927 |
0.6% | 1.0% |
1.6% 110k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
| South Africa |
23.8% 14,097,921 |
18.1% 10,759,755 |
1.0% | 1.4% |
1.9% 1,140k |
|
| Johnson&Johnson, Pfizer/BioNTech | ||||||
| Bangladesh |
23.4% 38,544,256 |
11.7% 19,332,082 |
1.0% | 0.6% |
1.6% 2,597k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing | ||||||
| Rwanda |
22.6% 2,928,553 |
13.3% 1,718,424 |
4.3% | 0.2% |
4.5% 577k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Bosnia and Herzegovina |
22.4% 734,195 |
15.5% 508,008 |
1.0% | 0.8% |
1.8% 58k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V | ||||||
| Botswana |
22.4% 525,739 |
11.0% 258,260 |
3.5% | 0.5% |
4.0% 94k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac | ||||||
| Zimbabwe |
21.8% 3,241,469 |
16.8% 2,501,519 |
0.4% | 0.6% |
1.0% 148k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac, Sputnik V | ||||||
| Libya |
21.4% 1,467,363 |
4.8% 331,651 |
0.5% | 0.9% |
1.4% 96k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V | ||||||
| Moldova |
20.5% 824,986 |
20.7% 836,013 |
0.5% |
0.6% 26k |
||
| Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
| Bulgaria |
20.3% 1,407,830 |
20.0% 1,393,292 |
0.3% |
0.6% 42k |
||
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Jamaica |
19.2% 569,913 |
11.8% 348,435 |
0.6% | 0.9% |
1.2% 36k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Ukraine |
18.8% 8,207,901 |
15.2% 6,658,010 |
1.2% | 0.9% |
2.1% 906k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac | ||||||
| Equatorial Guinea |
17.0% 237,751 |
12.9% 181,635 |
0.2% | 0.4% |
0.7% 9k |
|
| Sinopharm/Beijing | ||||||
| Lesotho |
16.2% 347,836 |
15.9% 339,506 |
0.7% | 0.7% |
0.7% 15k |
|
| Oxford/AstraZeneca | ||||||
| Myanmar |
15.4% 8,390,746 |
7.1% 3,872,956 |
2.2% | 0.3% |
2.4% 1,328k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Mauritania |
15.3% 712,117 |
12.7% 588,714 |
2.9% | 0.1% |
1.3% 61k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Kyrgyzstan |
14.2% 923,766 |
10.7% 700,281 |
0.6% | 0.5% |
1.1% 69k |
|
| Sinopharm/Beijing, Sputnik V | ||||||
| Algeria |
13.7% 6,017,036 |
9.2% 4,032,942 |
0.2% | 1.3% |
5.0% 2,204k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing, Sputnik V | ||||||
| Egypt |
13.2% 13,552,189 |
6.4% 6,602,177 |
2.1% | 0.6% |
2.7% 2,795k |
|
| Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V | ||||||
| Iraq |
13.1% 5,260,678 |
8.1% 3,246,256 |
0.5% | 0.2% |
0.7% 280k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
| Armenia |
11.6% 344,029 |
5.7% 170,212 |
1.2% | 0.4% |
1.7% 49k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac, Sputnik V | ||||||
| Angola |
11.5% 3,787,300 |
4.4% 1,437,397 |
2.0% | 0.5% |
2.5% 805k |
|
| Oxford/AstraZeneca | ||||||
| Namibia |
11.3% 285,993 |
8.2% 209,055 |
0.4% | 0.5% |
0.9% 23k |
|
| Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
| Togo |
10.5% 867,386 |
5.1% 419,768 |
0.7% | 0.1% |
0.9% 72k |
|
| Oxford/AstraZeneca | ||||||
| Guinea |
10.3% 1,355,165 |
5.0% 655,258 |
0.6% | 0.3% |
0.9% 119k |
|
| Sputnik V | ||||||
| Nicaragua |
10.1% 671,784 |
4.9% 328,206 |
1.7% | 0.3% |
2.1% 138k |
|
| Oxford/AstraZeneca, Sputnik V | ||||||
| Cote d'Ivoire |
7.8% 2,060,675 |
2.7% 701,472 |
0.4% | 0.4% |
0.8% 211k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing, Sputnik V | ||||||
| Senegal |
7.7% 1,280,390 |
5.2% 877,598 |
0.1% | 1.2% |
0.5% 83k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Gambia |
7.7% 184,817 |
7.1% 171,987 |
0.0% | 0.0% |
0.0% 1k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Mozambique |
6.3% 1,973,519 |
5.8% 1,808,510 |
0.2% | 0.1% |
0.3% 105k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Kenya |
6.2% 3,338,391 |
2.3% 1,252,334 |
0.3% | 0.3% |
0.6% 317k |
|
| Oxford/AstraZeneca, Sputnik V | ||||||
| Guinea-Bissau |
5.7% 111,771 |
0.5% 9,730 |
0.1% | 0.0% |
0.1% 2k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Gabon |
5.4% 120,033 |
3.9% 86,340 |
0.6% | 0.3% |
0.9% 20k |
|
| Sinopharm/Beijing | ||||||
| Uganda |
5.2% 2,378,171 |
0.9% 415,486 |
0.4% |
0.4% 178k |
||
| Oxford/AstraZeneca | ||||||
| Central African Republic |
5.1% 245,444 |
0.2% 9,901 |
0.5% |
0.5% 24k |
||
| Covaxin, Oxford/AstraZeneca | ||||||
| Congo |
5.1% 279,091 |
2.2% 119,594 |
0.5% | 0.0% |
0.5% 27k |
|
| Moderna, Oxford/AstraZeneca, Sinopharm/Beijing, Sputnik V | ||||||
| Malawi |
4.7% 895,463 |
2.7% 518,717 |
0.2% | 0.1% |
0.2% 33k |
|
| Johnson&Johnson, Oxford/AstraZeneca | ||||||
| Ghana |
4.4% 1,369,515 |
2.6% 820,037 |
0.7% | 0.1% |
0.8% 233k |
|
| Oxford/AstraZeneca, Sputnik V | ||||||
| Sierra Leone |
4.0% 318,380 |
1.4% 110,744 |
0.6% | 0.3% |
0.7% 59k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Syria |
3.9% 681,791 |
2.1% 367,744 |
0.2% | 0.1% |
0.3% 49k |
|
| Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V | ||||||
| Eswatini |
2.7% 236,992 |
2.7% 229,476 |
0.1% | 0.1% |
0.1% 12k |
|
| Oxford/AstraZeneca | ||||||
| Ethiopia |
2.7% 3,042,671 |
0.8% 964,972 |
0.1% | 0.0% |
0.1% 129k |
|
| Oxford/AstraZeneca | ||||||
| Nigeria |
2.6% 5,348,573 |
1.3% 2,681,129 |
0.1% | 0.2% |
0.3% 572k |
|
| Oxford/AstraZeneca | ||||||
| Somalia |
2.2% 355,132 |
1.8% 280,690 |
0.2% | 0.1% |
0.4% 59k |
|
| Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac | ||||||
| Afghanistan |
2.1% 828,601 |
1.1% 430,744 |
0.0% |
0.2% 91k |
||
| Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing | ||||||
| Niger |
2.0% 479,613 |
1.3% 323,533 |
0.1% | 0.3% |
0.5% 118k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Benin |
1.8% 216,527 |
1.5% 186,951 |
0.1% | 0.3% |
0.2% 20k |
|
| Oxford/AstraZeneca, Sinovac | ||||||
| Zambia |
1.7% 311,049 |
2.7% 497,977 |
0.2% |
0.2% 42k |
||
| Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Liberia |
1.7% 84,482 |
0.2% 9,135 |
0.0% | 0.0% |
0.0% 1k |
|
| Oxford/AstraZeneca | ||||||
| Mali |
1.6% 327,313 |
1.3% 257,460 |
0.0% | 0.0% |
0.4% 86k |
|
| Oxford/AstraZeneca | ||||||
| Cameroon |
1.5% 405,846 |
0.6% 150,894 |
0.0% | 0.0% |
0.0% 11k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Papua New Guinea |
1.5% 133,741 |
0.7% 61,221 |
0.2% | 0.2% |
0.3% 30k |
|
| Oxford/AstraZeneca | ||||||
| Sudan |
1.5% 649,062 |
1.3% 581,846 |
0.0% | 0.3% |
0.4% 156k |
|
| Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac | ||||||
| Burkina Faso |
1.3% 273,428 |
1.0% 208,994 |
0.1% | 0.1% |
0.1% 18k |
|
| Oxford/AstraZeneca | ||||||
| Yemen |
1.0% 308,025 |
0.2% 48,148 |
0.1% |
0.1% 16k |
||
| Johnson&Johnson, Oxford/AstraZeneca, Sinovac | ||||||
| Chad |
0.9% 155,038 |
0.3% 44,478 |
0.1% | 0.0% |
0.1% 17k |
|
| Sinopharm/Beijing | ||||||
| South Sudan |
0.8% 84,658 |
0.3% 35,809 |
0.0% | 0.0% |
0.1% 6k |
|
| Oxford/AstraZeneca | ||||||
| Madagascar |
0.7% 197,001 |
0.7% 184,632 |
0.3% |
0.2% 49k |
||
| Oxford/AstraZeneca | ||||||
| Haiti |
0.6% 73,568 |
0.2% 28,941 |
0.1% | 0.0% |
0.1% 12k |
|
| Johnson&Johnson, Oxford/AstraZeneca | ||||||
| Tanzania |
0.6% 350,000 |
1.5% 885,579 |
0.3% |
0.3% 170k |
||
| Johnson&Johnson | ||||||
| Democratic Republic of Congo |
0.1% 102,610 |
0.0% 37,644 |
0.0% | 0.0% |
0.0% 4k |
|
| Oxford/AstraZeneca | ||||||
| PEOPLE VACCINATED | LAST 7 DAYS | |||||
| countries below 1M population |
1st dose |
last dose |
1st dose |
last dose |
any dose |
|
| Gibraltar |
118.6% 39,972 |
118.0% 39,768 |
0.0% | 0.2% |
8.1% 3k |
|
| Pfizer/BioNTech | ||||||
| Pitcairn |
100.0% 47 |
100.0% 47 |
||||
| Oxford/AstraZeneca | ||||||
| Malta |
96.5% 426,203 |
96.3% 425,373 |
0.5% | 0.3% |
3.1% 14k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Cayman Islands |
84.9% 55,780 |
84.9% 55,780 |
0.4% | 0.4% |
2.2% 1k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Iceland |
82.7% 282,338 |
81.4% 277,837 |
0.1% | 0.2% |
1.2% 4k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Seychelles |
82.0% 80,595 |
76.0% 74,778 |
0.8% | 0.9% |
2.7% 3k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Faeroe Islands |
79.8% 38,970 |
76.1% 37,191 |
0.4% | 0.7% |
1.1% 1k |
|
| Moderna, Pfizer/BioNTech | ||||||
| Isle of Man |
79.2% 67,328 |
75.5% 64,207 |
2.2% | 0.2% |
2.4% 2k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Brunei |
77.6% 339,667 |
51.2% 224,028 |
4.0% | 3.5% |
7.5% 33k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Jersey |
77.4% 78,261 |
73.5% 74,327 |
0.1% | 0.1% |
1.5% 1k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Aruba |
76.9% 82,146 |
71.4% 76,187 |
0.2% | 0.4% |
0.6% 1k |
|
| Pfizer/BioNTech | ||||||
| Bhutan |
75.9% 585,479 |
65.1% 502,274 |
0.1% | 0.5% |
0.6% 4k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing | ||||||
| Falkland Islands |
75.6% 2,632 |
51.0% 1,775 |
0.8% | 1.7% |
2.4% 0k |
|
| Oxford/AstraZeneca | ||||||
| Niue |
74.3% 1,202 |
71.1% 1,150 |
17.9% |
18.2% 0k |
||
| Oxford/AstraZeneca | ||||||
| San Marino |
73.9% 25,084 |
65.5% 22,218 |
0.6% | 0.2% |
0.8% 0k |
|
| Pfizer/BioNTech, Sputnik V | ||||||
| Turks and Caicos Islands |
73.1% 28,305 |
67.4% 26,112 |
0.7% | 1.0% |
1.8% 1k |
|
| Pfizer/BioNTech | ||||||
| Bonaire Sint Eustatius and Saba |
72.9% 19,109 |
63.8% 16,736 |
2.5% | 2.8% |
5.2% 1k |
|
| Moderna, Pfizer/BioNTech | ||||||
| Maldives |
72.8% 393,679 |
65.0% 351,169 |
0.1% | 1.0% |
1.1% 6k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing | ||||||
| Bermuda |
72.3% 45,017 |
69.7% 43,400 |
0.7% | 0.4% |
1.1% 1k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Greenland |
70.5% 40,033 |
64.7% 36,724 |
0.1% | 0.6% |
0.7% 0k |
|
| Moderna | ||||||
| Andorra |
70.3% 54,312 |
61.8% 47,720 |
0.4% | 1.5% |
2.0% 2k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Nauru |
70.3% 7,612 |
66.9% 7,251 |
0.2% |
0.2% 0k |
||
| Oxford/AstraZeneca | ||||||
| Cook Islands |
70.0% 12,297 |
63.7% 11,192 |
2.7% | 0.2% |
2.9% 1k |
|
| Pfizer/BioNTech | ||||||
| Fiji |
69.1% 619,734 |
57.7% 517,175 |
1.6% | 3.3% |
4.9% 44k |
|
| Oxford/AstraZeneca | ||||||
| Cyprus |
68.7% 601,435 |
64.7% 566,531 |
0.2% | 0.3% |
1.4% 13k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Monaco |
68.0% 26,672 |
59.4% 23,308 |
0.6% | 1.3% |
1.8% 1k |
|
| Pfizer/BioNTech | ||||||
| Luxembourg |
67.8% 424,732 |
63.8% 399,522 |
0.5% |
1.1% 7k |
||
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Macao |
65.5% 425,260 |
50.7% 328,961 |
3.8% | 1.1% |
4.8% 31k |
|
| Pfizer/BioNTech, Sinopharm/Beijing | ||||||
| Liechtenstein |
65.0% 24,787 |
60.7% 23,166 |
0.1% | 0.4% |
0.4% 0k |
|
| Moderna, Pfizer/BioNTech | ||||||
| Anguilla |
63.6% 9,548 |
61.0% 9,157 |
||||
| Oxford/AstraZeneca | ||||||
| Sint Maarten (Dutch part) |
60.9% 26,122 |
56.2% 24,101 |
0.2% | 0.1% |
0.2% 0k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Curacao |
60.5% 99,260 |
55.6% 91,311 |
0.3% | 0.5% |
0.8% 1k |
|
| Moderna, Pfizer/BioNTech | ||||||
| New Caledonia |
60.0% 171,401 |
49.4% 141,123 |
3.5% | 8.0% |
11.5% 33k |
|
| Pfizer/BioNTech | ||||||
| British Virgin Islands |
58.2% 17,607 |
51.2% 15,468 |
0.1% | 0.4% |
0.5% 0k |
|
| Johnson&Johnson, Oxford/AstraZeneca | ||||||
| Samoa |
58.1% 115,354 |
37.0% 73,310 |
0.1% | 2.8% |
2.9% 6k |
|
| Oxford/AstraZeneca | ||||||
| Antigua and Barbuda |
56.3% 55,103 |
47.3% 46,287 |
0.7% | 1.9% |
2.6% 3k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sputnik V | ||||||
| French Polynesia |
55.3% 155,290 |
52.4% 147,185 |
0.4% | 1.0% |
1.4% 4k |
|
| Johnson&Johnson, Pfizer/BioNTech | ||||||
| Cape Verde |
51.5% 286,160 |
33.5% 186,276 |
0.3% | 3.2% |
1.9% 10k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Wallis and Futuna |
51.4% 5,781 |
47.3% 5,321 |
0.5% | 0.8% |
1.2% 0k |
|
| Moderna | ||||||
| Barbados |
50.5% 144,981 |
40.5% 116,514 |
1.1% | 1.7% |
2.8% 8k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing | ||||||
| Belize |
50.3% 199,932 |
36.3% 144,531 |
1.5% | 4.3% |
5.8% 23k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Saint Kitts and Nevis |
49.3% 26,249 |
43.4% 23,069 |
0.6% | 0.5% |
1.1% 1k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Guernsey |
49.2% 32,969 |
20.3% 13,618 |
0.3% 0k |
|||
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Tonga |
47.1% 49,817 |
28.6% 30,245 |
1.4% | 1.4% |
2.8% 3k |
|
| Oxford/AstraZeneca | ||||||
| Guyana |
47.0% 369,877 |
28.8% 226,649 |
0.7% | 1.4% |
2.1% 17k |
|
| Oxford/AstraZeneca, Sputnik V | ||||||
| Suriname |
41.5% 243,328 |
32.2% 188,825 |
0.9% | 1.3% |
2.2% 13k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing | ||||||
| Montenegro |
40.4% 253,486 |
37.1% 233,183 |
0.3% | 1.2% |
1.5% 9k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
| Dominica |
37.2% 26,806 |
30.6% 22,024 |
0.7% | 0.3% |
1.0% 1k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing | ||||||
| Kiribati |
36.0% 43,044 |
7.0% 8,384 |
4.5% | 0.5% |
5.0% 6k |
|
| Oxford/AstraZeneca | ||||||
| Sao Tome and Principe |
34.6% 75,837 |
12.7% 27,883 |
1.8% | 0.4% |
2.2% 5k |
|
| Oxford/AstraZeneca | ||||||
| Bahamas |
34.0% 133,591 |
28.1% 110,710 |
1.1% | 2.7% |
3.5% 14k |
|
| Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Grenada |
32.7% 36,757 |
25.4% 28,605 |
0.9% | 2.0% |
2.9% 3k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Montserrat |
30.0% 1,502 |
28.2% 1,409 |
0.2% |
0.4% 0k |
||
| Oxford/AstraZeneca | ||||||
| Comoros |
28.2% 245,694 |
18.6% 162,098 |
3.8% |
3.8% 33k |
||
| Covaxin, Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Saint Lucia |
26.9% 49,423 |
20.7% 38,023 |
0.8% | 1.0% |
1.7% 3k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Saint Vincent and the Grenadines |
20.9% 23,127 |
13.4% 14,903 |
1.0% | 0.6% |
1.7% 2k |
|
| Oxford/AstraZeneca | ||||||
| Vanuatu |
19.3% 59,215 |
9.2% 28,368 |
3.1% | 1.4% |
4.5% 14k |
|
| Oxford/AstraZeneca | ||||||
| Solomon Islands |
16.5% 113,423 |
4.2% 28,497 |
1.3% | 0.4% |
1.7% 12k |
|
| Oxford/AstraZeneca | ||||||
| Djibouti |
6.7% 66,010 |
2.6% 26,087 |
2.2% |
2.2% 22k |
||
| Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V | ||||||